A method for measuring the concentration of a compound in the blood of a part of a subject is provided. An invasive or non-invasive sample of blood may used for this determination. Also provided is a device for measuring the concentration of a compound in the blood of a subject.
|
1. A device for measuring a concentration of one or more than one compound in a sample derived from a body part of a subject, wherein the sample is measured on the surface of the body part without handling of the sample, comprising:
a source of electromagnetic radiation (emr) that emits one or more than one wavelength of emr, the source of emr being operatively coupled to a power source;
a probe comprising one or more than one input radiation guiding element in operable association with the source of emr, one or more than one output radiation guiding element in operable association with a detector, the one or more than one input radiation guiding element and the one or more than one output radiation guiding element optically aligned with one or more than one port located within the probe to define-an emr path through the probe;
a detachable receptor received within the probe and sized to receive the body part, the receptor comprising one or more than one port in optical alignment with the one or more than one port located within the probe to further define the emr path through the probe and within the receptor;
a lancing device and a guide for targeting the lancing device, the lancing device and guide positioned within the receptor to produce a sample from the body part that is disposed on the surface of the body part and directly within the emr path; and
a detector for measuring transmitted or reflected emr received directly from the sample on the surface of the body part without handling of the sample; and
a processing system operatively coupled to the detector, comprising one, or more than one calibration algorithm for determining a concentration for the one or more than one compound;
wherein the probe and the receptor received within the probe are removable from the source of emr, the detector, or both the source of emr and detector, and are optically associated with the source of emr and the detector.
2. The device according to
3. The device according to
4. The device according to
5. The device according to
6. The device according to
7. The device according to
8. A method of determining the concentration of one or more than one compound in a sample of blood on the surface of a body part of a subject without handling of the sample, using the device defined in
(a) placing the receptor of the device according to
(b) directing the source of electromagnetic radiation (emr) of the device according to
(c) measuring on the surface of the body part without handling of the sample, a quantity of the emr reflected by, or transmitted through, the sample of blood with the detector of the device according to
(d) performing a quantitative mathematical analysis of the quantity of emr using the one, or more than one calibration algorithm of the processing system of the device according to
9. The method according to
10. The method according to
11. The method according to
12. The method according to
13. The method according to
14. The method according to
15. The method according to
16. The method according to
17. A method of determining the concentration of one or more than one compound in a sample of blood on the surface of a body part of a subject without handling of the sample, using the device defined in
(a) placing the receptor of the device according to
(b) lancing the body part located within the receptor with the lancing device to produce a sample of blood from the body part that is disposed on the surface of the body part and directly within the emr path,
(c) directing the source of electromagnetic radiation (emr) of the device according to
(d) measuring on the surface of the body part without handling of the sample, a quantity of the emr reflected by, or transmitted through, the sample of blood with the detector of the device according to
(e) performing a quantitative mathematical analysis of the quantity of emr using the one, or more than one calibration algorithm of the processing system of the device according
18. The method according to
19. The method according to
20. The method according to
21. The method according to
22. The method according to
23. The device according to
24. The device according to
25. The device according to
26. The device according to
27. The method according to
28. The method according to
29. The method according to
30. The method according to
31. The method according to
32. The method according to
33. The method according to
34. The method according to
|
|||||||||||||||||||||||||||||
This application claims the benefit of U.S. Provisional Application Ser. No. 60/714,476, filed Sep. 6, 2005. This provisional application is incorporated by reference.
The present invention relates to a method of measuring the concentration of a compound in a sample on the surface of a part of a subject. The present invention also provides a device for carrying out the method.
The concentration of a compound within blood of a subject may be measured using invasive techniques, for example obtaining a blood sample and placing the sample on a device that is introduced into a spectrophotometer. Alternatively, the concentration of the compound may be determined non-invasively by placing a part of the body within a receptor that is coupled to a spectrophotometer, as disclosed in for example, U.S. Pat. No. 5,361,758 (Hall et al.) or U.S. Pat. No. 6,741,876 (Seciena et al.).
Clinical studies have revealed that the concentration of certain compounds in a body part of a subject may be used to assess the risk of development of specific medical conditions in that subject. Early detection of these types of risks in a patient permits measures to be taken that may slow or even prevent the onset of these conditions. As an example, it has been determined that elevated concentration of cholesterol is an indication of a risk for coronary disease. Similarly, the determination of blood glucose levels is required by diabetic patients. Therefore, the development of simple, methods for determining the concentration of a compound is of importance.
In U.S. Pat. No. 6,365,363, Parfeiiov et al. describe a method of indirectly measuring the concentration of cholesterol in the skin of a subject by enzymatically oxidizing the cholesterol in a section of the subject's skin and then quantitating the amount of the hydrogen peroxide by-product stoichiometrically formed in this reaction using a second enzymatic reaction. As a complex series of enzymatic reactions are used in this method to indirectly determine the concentration of cholesterol, the method is both costly and prone to error. In addition, the development of a result using this method is time consuming.
In U.S. Pat. Nos. 6,236,047 and 6,040,578, Malin et al. describe a method for determining the concentration of a blood compound using light in the near infrared range by analyzing diffusively reflecting radiation emerging from the irradiated sample. Hall et al. also describe in U.S. Pat. No. 5,361,758 a non-invasive technique for directly measuring the concentration of constituents of blood using light in the near-infrared range.
Invasive methods for the assay of a compound involve lancing a body part to produce a blood sample and placing anywhere from about 2 to about 250 μl, or more, of the sample within a sample holding device are known, for example a slide well (U.S. Pat. No. 4,387,972, Valencia; U.S. Pat. No. 5,800,781, Gavin et al.; U.S. Pat. No. 5,207,984, Kheiri), a sample tab (e.g. WO 00/70350, Samsoondar) or filter paper strip or the like. The sample holder may then be introduced within a receptor of the sample holding device of a spectrophotometer to determine the concentration of the sample (e.g. WO 98/39634, Samsoondar; WO 99/47261, Samsoondar). This process may be awkward, typically require significant sample volumes, and may require the use of additional devices, for example a capillary tube (e.g. U.S. Pat. No. 4,791,938, Valkenburg) to collect the sample from the body part and transfer the sample to the holding-device. Furthermore, as the blood sample is being transferred to a sample holding device, the chance for contamination from an exposed blood sample is present.
Alvarez et al. (U.S. Pat. No. 5,912,179) disclose a method of determining the level of oxidative stress of a tissue sample based on the state of oxidation of unsaturated fatty acids using, for example, infrared spectrometry. Chemical features used to determine the oxidative state of unsaturated fatty acids include cis-type double bonds, vinyl protons and vinyl hydroperoxyl groups of the fatty acids in the sample.
The present invention relates to a method of measuring the concentration of a compound in a sample on the surface of a part of a subject. The present invention also provides a device for carrying out the method.
It is an object of the invention to provide an improved method and apparatus for determining the concentration of an analyte,
According to the present invention there is provided a device for measuring a concentration of one or more than one compound in a sample, comprising:
The detachable receptor of the device as described above may be sized to fit over a portion of a body part, sized to fit over a drop of blood located on the body part. Furthermore, the detachable receptor may comprise a matrix that can wick the sample off a surface of a body part. The detachable receptor, or the holder may further comprise an apparatus for lancing a body part when the body part is positioned with the receptor.
The device as described above may further comprise a second path of EMR through the holder and within the detachable receptor, wherein the second path of EMR interacts with the sample at a location separate from that of the EMR path, the second path of EMR is in operative association with the source of EMR or a second source of EMR.
The present invention is also directed to the device as defined above, wherein the holder is a probe, and the probe may be removed from the source of EMR, the detector, or both the source of EMR and detector, but remain in optical association with the source of EMR and the detector.
The present invention also pertains to the device as defined above, wherein the source of EMR comprises wavelengths from about 300 nm to about 2500 nm, or from about 500 nm to about 1100 nm.
The present invention provides a method (A) of determining the concentration of one or more than one compound in a sample of blood comprising,
(a) placing a receptor over a portion of a body part, the body part having a sample of blood thereon,
(b) directing a source of electromagnetic radiation (EMR) through the receptor and onto the sample of blood;
(c) measuring a quantity of the EMR reflected by, or transmitted through, the sample of blood with a detector; and
(d) performing a quantitative mathematical analysis of the quantity of EMR using an algorithm, and determining the concentration of the one or more than one compound in the sample of blood.
The present invention pertains to the method (A) as defined above, wherein the one or more than one compound may be selected from the group consisting of a fat, a protein, a glycoprotein, hemoglobin, Oxy-Hb, % oxy-Hb, “Oxy-Hb plus Deoxy-Hb”, “Total-Hb minus Met-Hb”, Met-Hb, % met-Hb, Carboxy-Hb, Co-Hb, Sulf-Hb, HbAlc, cholesterol, glucose, a fat, a protein, a glycoprotein, a lipoprotein, a carbohydrate, a steroid, an amino acid, nitrogen, carbon dioxide, cortisol, creatine, creatine, a ketone, a lipid, urea, a fatty acid (such as an omega-3 fatty acid, for example, but not limited to α-linolenic acid, eicosapenitaenoic acid, or docosalhexaecnoic acid; an omega-6 fatty acid, for example, but not limited to linoleic acid, gamma-linolenic acid, eicosadienioic acid, dihomo-gamma-linolenic acid, arachidonic acid, docosadienoic acid, adrenic acid, or docosapentaenoic acid; or an omega-9 fatty acid, for example, but not limited to oleic acid, eicosenoic acid, mead acid, etucic acid or nervonic acid), glycosolated hemoglobin, alcohol, lactate, an ion, Ca2+, K+, Cl−, HCO3− and HPO4−.
The present invention embraces the method (A) as described above, wherein prior to the step of placing (step a)), the body part is lanced so that the sample of blood is produced on the surface of the body part. Prior to the step of placing (step (a)), the receptor is placed within a holder, and after the step of measuring (step (c)) the receptor is removed from the holder. Furthermore, the present invention includes the method (A) as defined above, wherein in the step of placing (step (a)), the sample may be wicked within the receptor. The present invention also provides for the method (A) as defined above, wherein the source of EMR comprises wavelengths from about 300 nm to about 2500 nm, or from about 500 nm to about 1100 nm.
The present invention also pertains to the method (A) as defied above, wherein in the step of directing (step (b)), a second source of EMR is directed to the body part, and a measurement of background is obtained. Alternatively, the second source of EMR may be directed to the body part, and in the step of measuring (step (c)), a non-invasive measurement is made of one or more than one compound within the body part, which may be the same as or different from the one or more than one compound measured in the sample of blood.
The present invention also pertains to a method (B) of determining the concentration of one or more than one compound in a sample of blood comprising,
(a) placing, a receptor over a portion of a body part;
(b) lancing the body part located within the receptor to produce a sample of blood on the surface of the body part,
(c) directing a source of electromagnetic radiation (EMR) through the receptor and onto the sample of blood;
(d) measuring a quantity of the EMR reflected by, or transmitted through, the sample of blood with a detector; and
(e) performing a quantitative mathematical analysis of the quantity of EMR using an algorithm, and determining the concentration of the one or more than one compound in the sample of blood.
The present invention pertains to the method (B) as defined above, wherein the one or more than one compound may be selected from the group consisting of a fat, a protein, a glycoprotein, hemoglobin, Oxy-Hb, % oxy-Hb, “Oxy-Hb plus Deoxy-Hb”, “Total-Hb Minus Met-Hb”, Met-Hb, % met-Hb, Carboxy-Hb, Co-Hb, Sulf-Hb, HbAlc, cholesterol, glucose, a fat, a protein, a glycoprotein, a lipoprotein, a carbohydrate, a steroid, an amino acid, nitrogen, carbon dioxide, cortisol, creatine, creatimine, a ketone, a lipid, urea, a fatty acid (such as an omega-3 fatty acid, for example, but not limited to α-linolenic acid, eicosapenitaenoic acid, or docosapentaenoic acid; an omega-6 fatty acid, for example, but not limited to linoleic acid, gamma-linolenic acid, eicosadienioic acid, dihomo-gamma-linolenic acid, arachidonic acid, docosadienoic acid, adrenic acid, or docosapentaenoic acid; or an omega-9 fatty acid, for example, but not limited to oleic acid, eicosenoic acid, mead acid, erucic acid or nervonic acid), glycosolated hemoglobin, alcohol, lactate, an ion, Ca2+, K+, Cl−, HCO3− and HPO4−.
The present invention is directed to the method (B) as defined above, wherein prior to the step of placing (step (a)), the receptor is placed within a holder, and after the step of measuring (step (d)) the receptor is removed from the holder. Furthermore, in the step of placing (step (a)), the sample may be wicked within the receptor.
The present invention also provides for the method (B) as defined above, wherein the source of EMR comprises wavelengths from about 300 nm to about 2500 nm, or from about 500 nm to about 1100 nm.
The present invention also pertains to the method (B) as defined above, wherein in the step of directing (step (c)), a second source of EMR is directed to the body part, and a measurement of background is obtained. Alternatively, the second source of EMR may be directed to the body part, and in the step of measuring (step (d)), a non-invasive measurement is made of one or more than one compound within the body part, which may be the same as or different from the one or more than one compound measured in the sample of blood.
Using the device and method of the present invention, the measured concentration of the one or more than one compound may also be correlated to a specific clinical condition or to the propensity for a specific clinical condition.
By determining the concentration of a compound within a sample localized on a surface of a body part, minimal volumes of the sample, for example blood, are required. Furthermore, by placing the receptor of the device directly over the sample, a minimal amount of sample handling is required prior to assay. Providing a receptor that combines the lancing of the body part within the receptor, ensures alignment of the sample within the receptor with the source of EMR, so that the path of EMR interacts with the sample with minimal background effects. Similarly, by providing a receptor that wicks the sample from the surface of the body part and towards the input and output ports of the receptor, ensures that the sample is in optical alignment with the path of EMR and retained within the receptor. The device and methods for obtaining a concentration of a compound within the sample as disclosed herein result in a safe, simple, and efficient method of assaying a compound within a sample. Furthermore, since there is no sample handling, the method and device of the present invention requires the use of a minimal amount of sample for the determination procedure.
This summary of the invention does not necessarily describe all features of the invention.
These and other features of the invention will become more apparent from the following description in which reference is made to the appended drawings wherein:
The present invention relates to a method of measuring the concentration of a compound in a sample on the surface of a part of a subject. The present invention also provides a device for carrying out the method.
The following description is of a preferred embodiment.
With reference to
The source of EMR (10) preferably emits one or more than one wavelength of EMR. For example, which is not to be considered limiting in any manner, the source of EMR may emit one or more than one wavelength of EMR over a range of wavelengths from about 300 nm to about 20,000 nm, or any wavelength therebetween as desired. For example from about 300 nm to about 3,000 nm or any wavelength therebetween, or from about 500 nm to about 2,500 nm or any wavelength therebetween. The source of EMR may be a polycromatic source, an LED source, a laser source, or another source suitable for irradiating a sample at one or more than one desired wavelengths. The source of EMR, and the range of wavelengths emitted by the EMR source is not to be considered limiting in the present invention. The source of EMR is operatively coupled to any suitable power source (5) as would be known to one of skill in the art.
The near infrared region of the electromagnetic spectrum is generally considered to be the spectral interval extending from 650 nm through to 2700 nm and measurements of samples as described herein may be obtained from about 700 nm to about 1100 nm range. Absorption bands observed in this interval are primarily the combination and overtone bands of the fundamental infrared bands. Although very weak in intensity, being typically less than one-tenth in intensity of the fundamental infrared bands, these bands are considered to be analytically useful because nearly all chemical species exhibit characteristic absorption bands in this spectral interval. The near infrared region is particularly well-suited to invasive and non-invasive diagnostic applications because biological samples, or human tissue are somewhat transparent to the incident radiation and therefore sufficient penetration of the radiation is possible to allow accurate quantitative analysis.
The source of EMR used in the present invention to detect the one or more than one compound in the sample or body part is preferably near-infrared light, for example but not limited to a polycromatic light source. This type of light source can emit light over a very wide bandwidth including light in the near infrared spectrum. In this case, the light from the light source preferably passes first through a collimator, which is a collection of lenses that concentrate the light into a narrow parallel beam directed at the receptor. The polychromatic light source can comprise a quartz-halogen or a tungsten-halogen bulb to provide the broad spectrum of light in the near infrared, and is powered by a stabilized power source, for example, a DC power supply, or by a battery. This polycromatic light source may be a tungsten-halogen lamp or it may be a collection of LEDs or other light sources selected to emit radiation in the range of about 650 to about 1100 nm. More particularly, the polychromatic light source comprises a source of light that emits a wavelength of light in the visible red spectrum, for example, 660 nm, a wavelength of light in the infrared spectrum, for example, 940 nm, and a broad spectrum of light in the near infrared region.
In a particular non-limiting example, the polychromatic light source may comprise a pair of light emitting diodes that provide light at the wavelengths of 660 nm and 940 nm for detecting the value of oxygen saturation of blood in the part, and a broad band light source that emits a broad spectrum of light in the near infrared. Additional sources of EMR may also be used to determine the concentration of additional compounds with the sample. The light emitting diodes and the broad band light sources may be activated simultaneously, or sequentially so that the is concentration of the compound in the sample or body part, and the value of oxygen saturation in the blood are either determined simultaneously, or in a step-wise manner. The one or more than one compound, the oxygen saturation, or a combination thereof may be determined as a concentration value, or as a percentage, for example, a percentage of one compound relative to one or more than one other compound in the sample. In addition, the light emitting diodes may be cycled on and off, many times per second, during the process of acquiring absorbance or transmission data to help eliminate background noise.
The device (1) may be fitted with a holder (70) for receiving a detachable receptor (20). The holder comprises one or more than one radiation guiding elements, for example one or more than one input (40) in operable association with the source of EMR (10), and one or more than one output (50) in operable association with the detector (30). The one or more than one input (40) and the one or more than output (50) of the holder (70) are in an optical alignment with one or more than one port located within the holder (see 145, 155,
The radiation guiding elements (40, 50) may be any suitable element for transmitting radiation, for example but not limited to one or more than one fiber optic bundles, or radiation guiding rods, for example but not limited to fused silica rods. The radiation guiding elements may also be coupled together, so that for example the input path of EMR may pass through an optical fiber oriented circumferentially around a central optical fiber that is used to receive the output EMR, or visa versa. Additional beam-forming elements such as lenses (e.g. 90, 100,
The receptor (20) may comprise one or more than one input and one or more than one output ports (e.g. 157,
The receptor (20) matingly engages with the holder (70) and can easily be removed from the holder after use. The receptor may be in press fit engagement with the holder, snap into place, be retained via any suitable biasing means, for example a spring, and the like. If desired, a tab may be added to the receptor to facilitate installation and removal of the receptor from the holder.
The receptor (20) may be sized to fit over the sample (80) located on the surface of a body part (60) as shown in
The receptor may be made from a material that can be discarded after use to minimize contamination from the sample.
The receptor may also comprise a material (25,
In an alternative embodiment of the present invention, the receptor may also comprise a device for lancing the body part (120,
In another alternative embodiment, the holder (70) may also receive a suitable sized sample holder, for example a slide well (U.S. Pat. No. 4,387,972, Valencia; U.S. Pat. No. 5,800,781, Gavin et al.; U.S. Pat. No. 5,207,984, Kheiii), a sample tab (eg. WO 00/70350, Samsoondar), a filter paper strip or the like. The sample holder may be introduced within the holder (70) of the device of the present invention to determine the concentration of the sample. In this embodiment, the lid of the sample tab, or slide well is transparent or comprises transparent portions to permit the entry and exit of EMR to interact with the sample.
The reflected, transmitted, or both, EMR following interaction with the sample is collected by using any suitable method, for example, fiber optics, or one or more lenses (e.g. 90, 100), and the output signal (50) directed to a diffraction device that separates the wavelengths of light within the output signal into their component parts. Examples of a diffraction device include but are not limited to a diffraction grating or a holographic grating. The diffiacting device preferably disperses the EMR into its component wavelengths so that the dispersed EMR falls along the length of a detector such as, but not limited to a linear array detector (e.g. a 256 element photo diode array), or a CCD. In the case of an allay, the detector has a series of diodes and is preferably electronically scanned by a microprocessor to measure the charge accumulated on each diode, the charge being proportional to the intensity of EMR for each wavelength transmitted through or reflected from the part of the subject in the receptor.
The detector is connected to the microprocessor, producing an output spectrum, with the microprocessor analyzing the measurements and ultimately producing a result for each concentration level determined. The processing may comprise one or more than one calibration algorithm (for example as disclosed in U.S. Pat. No. 6,651,015, Samsoondar, which is incorporated herein by reference) that is used to determine a property of one or more than one compound within the sample (80). The result can be stored, shown on a display, or printed on a printer. A keyboard may also be used to allow a user to control the device, for example, to specify a particular constituent to be measured. The timing and control may be activated by a microprocessor to control the device, for example, to determine number and timing of measurements.
If required, the device (1) may also have a second path of EMR (57,
Therefore, the present invention provides a device for measuring a concentration of one or more than one compound in a sample, comprising:
a source of electromagnetic radiation (EMR) that emits one or more than one wavelength of EMR, the source of EMR being operatively coupled to a power source;
a holder for receiving a detachable receptor, the holder comprising one or more than one input in operable association with the source of EMR, one or more than one output in operable association with a detector, the one or more than one input and the one or more than output of the holder in optical alignment with one or more than one port located within the receptor, the one or more than one input and the one or more than one output defining an EMR path through the holder and within the receptor, wherein, the sample when received by the receptor is placed within the EMR path;
the detector for measuring transmitted or reflected EMR received from the sample, the detector operatively coupled to a processing system;
the processing system comprising one or more than one calibration algouithim for determining a concentration for the one or more than one compound.
The device of the present invention may be used to determine the concentration of one or more than one compound, or a percentage of a compound with reference to another compound (i.e. the relative abundance of one compound with respect to another compound) within the sample. The compound may be any compound, and the invention is not meant to be limited by the compound, or compounds, being assayed. For example, which is not to be considered limiting, if the sample is a biological fluid, the compound may be selected from the group consisting of a fat, a protein, a glycoprotein, hemoglobin, Oxy-Hb, % oxy-Hb, “Oxy-Hb plus Deoxy-Hb”, “Total-Hb minus Met-Hb”, Met-Hb, % met-Hb, Carboxy-Hb, Co-Hb, Sulf-Hb, HbAIc, cholesterol, glucose, a fat, a protein, a glycoprotein, a lipoprotein, a carbohydrate, a steroid, an amino acid, nitrogen, carbon dioxide, cortisol, creatine, creatine, a ketone, a lipid, urea, a fatty acid (such as an omega-3 fatty acid, for example, but not limited to α-linolenic acid, eicosapenitaenoic acid, or docosapentaenoic acid, an omega-6 fatty acid, for example, but not limited to linoleic acid, gamma-linolenic acid, eicosadienioic acid, dihomo-gamma-linolenic acid, arachidonic acid, docosadienoic acid, adrenic acid, or docosapentaenoic acid; or an omega-9 fatty acid, for example, but not limited to oleic acid, eicosenoic acid, mead acid, emetic acid or nervonic acid), glycosolated hemoglobin, alcohol, lactate, an ion, Ca2+, K+, Cl−, HCO3− and HPO4−.
The processing system of the device of the present invention may be used to determine the oxygen saturation of blood in the part by analyzing the differential absorption of oxygenated hemoglobin, HbO2, and deoxygenated hemoglobin, Hb in arterial blood. Based on the absorbances of the wavelengths of light in the visible red and infrared spectra, the system can calculate a value of arterial oxygen saturation (SpaO2) of hemoglobin in the blood of the subject. The system can distinguish hemoglobin absorption from absorption of other components of the tissues within the part based upon the pulsatile nature of arterial blood. In this embodiment, the processing system may further comprise a pulse oximeter.
The concentration of a given compound is preferably calculated according to the present invention by using a calibration equation derived from a statistical analysis, for example but not limited to a least squares best fit, of a plot of the values of concentration of a calibration set of samples of the compound, which are determined using known methods (e.g. U.S. Pat. No. 6,651,015. Samsoondar). However, it is to be understood that other statistical tests may be used was known in the art, for example but not limited to multiple linear regression (MLR), partial least squares (PLS), and the like. Any known method for determining the concentration of one, or more than one, compound may be used as would be known to one of skill in the art.
The present invention also provides a method to determine the concentration of one or more than one compound within the sample and a similar or different compound within the body part that lies along the paths of ENR emitted, and received by, the receptor. In this example, there are two sources of EMR traveling within two paths of EMR. One path of EMR interacts with the sample, for example a drop of blood, while the second path of EMR may interact with the body part in a non-invasive manner, as shown in
The present invention also provides for a method of determining the concentration of a compound in a sample of blood comprising,
(a) placing a receptor over a portion of a body part, the body part having a sample thereon, the sample may be blood;
(b) directing a source of electromagnetic radiation (EMR) through the receptor and onto the sample;
(c) measuring a quantity of the E/R reflected by, or transmitted through, the sample with a detector; and
(d) performing a quantitative mathematical analysis of the quantity of EMR using an algorithm, and determining the concentration of the compound in the sample.
Prior to the step of placing (step a)), the body part may be pricked or lanced so that the sample is a sample of blood, and the blood is produced on the surface of the body part.
Furthermore, the present invention provides a method of determining the concentration of a compound in a sample of blood comprising,
(a) placing a receptor over a portion of a body part;
(b) lancing the body part located within the receptor to produce a sample of blood on the surface of the body part.
(b) directing a source of electromagnetic radiation (EMR) through the receptor and onto the sample of blood;
(c) measuring a quantity of the EMR reflected by, or transmitted through, the sample of blood with a detector; and
(d) performing a quantitative mathematical analysis of the quantity of EMR using an algorithm, and determining the concentration of the compound in the sample of blood.
All citations are hereby incorporated by reference.
The present invention has been described with regard to one or more embodiments. However, it will be apparent to persons skilled in the art that a number of variations and modifications can be made without departing from the scope of the invention as defined in the claims.
MacIntyre, Duncan, Kaushal, Ash, Endersby, Paul
| Patent | Priority | Assignee | Title |
| 10835130, | Dec 19 2014 | Samsung Electronics Co., Ltd. | Noninvasive blood glucose measurement method and apparatus |
| Patent | Priority | Assignee | Title |
| 4387972, | Feb 26 1981 | Immuno Concepts, Inc. | Microscope slide with confirming wells |
| 4637403, | Apr 08 1985 | KUDD, ARTHUR R ; DAYTON, JUDSON M | Glucose medical monitoring system |
| 4791938, | Nov 16 1987 | Capillary blood collector and method | |
| 5207984, | Mar 11 1991 | Miles Inc. | Blood sample collection and test device |
| 5361758, | Jun 09 1988 | Nellcor Puritan Bennett LLC | Method and device for measuring concentration levels of blood constituents non-invasively |
| 5522388, | Sep 22 1993 | Kowa Company Ltd. | Pulse spectrometer |
| 5736103, | Aug 09 1996 | LifeScan, Inc. | Remote-dosing analyte concentration meter |
| 5796476, | Jun 28 1995 | Kyoto Dai-Ichi Kagaku Co., Ltd. | Method of optically measuring component in solution |
| 5800781, | Oct 21 1994 | International Technidyne Corporation | Blood sampling device |
| 5912179, | Aug 22 1994 | Beth Israel Deaconess Medical Center, Inc. | Method for determining a level of oxidative stress of a tissue sample |
| 6040578, | Feb 02 1996 | GLT ACQUISITION CORP | Method and apparatus for multi-spectral analysis of organic blood analytes in noninvasive infrared spectroscopy |
| 6099484, | May 16 1997 | Roche Diabetes Care, Inc | Methods and apparatus for sampling and analyzing body fluid |
| 6236047, | Feb 02 1996 | GLT ACQUISITION CORP | Method for multi-spectral analysis of organic blood analytes in noninvasive infrared spectroscopy |
| 6353471, | Oct 10 1995 | Covidien LP | Method and apparatus for non-destructive screening of specimen integrity |
| 6365363, | Feb 20 1997 | IMI International Medical IInnovations, Inc. | Method of determining skin tissue cholesterol |
| 6430513, | Sep 04 1998 | PerkinElmer Instruments LLC | Monitoring constituents of an animal organ using statistical correlation |
| 6526298, | May 18 1998 | Abbott Laboratories | Method for the non-invasive determination of analytes in a selected volume of tissue |
| 6651015, | Nov 23 1999 | Covidien LP | Method for calibrating spectrophotometric apparatus |
| 6741876, | Aug 31 2000 | Covidien LP | Method for determination of analytes using NIR, adjacent visible spectrum and discrete NIR wavelenths |
| 6819950, | Oct 06 2000 | Woolsthorpe Technologies | Method for noninvasive continuous determination of physiologic characteristics |
| 6849052, | Dec 13 1999 | ARKRAY, Inc | Body fluid measuring apparatus with lancet and lancet holder used for the measuring apparatus |
| 7016021, | Jun 19 2002 | OMRON HEALTHCARE CO , LTD | Method for measuring concentration of component contained in bodily fluid and apparatus for measuring concentration of component contained in bodily fluid |
| 7050157, | Nov 08 2001 | OptiScan Biomedical Corporation | Reagent-less whole-blood glucose meter |
| 7194369, | Jul 23 2001 | EUROFINS QTA INC | On-site analysis system with central processor and method of analyzing |
| 7343185, | Jun 21 2002 | Covidien LP | Measurement of body compounds |
| 7377794, | Mar 01 2005 | WILLOW LABORATORIES, INC | Multiple wavelength sensor interconnect |
| 7524671, | Jan 27 2005 | PRESCIENT MEDICAL, INC | Handheld raman blood analyzer |
| 20030086073, | |||
| 20030204133, | |||
| 20040073120, | |||
| 20040260204, | |||
| 20050019936, | |||
| 20050036147, | |||
| 20050250212, | |||
| 20060167382, | |||
| 20090168049, | |||
| 20090221886, | |||
| CA2475622, | |||
| WO70350, | |||
| WO20060181380, | |||
| WO9839634, | |||
| WO9947261, |
| Executed on | Assignor | Assignee | Conveyance | Frame | Reel | Doc |
| Aug 08 2006 | Covidien LP | (assignment on the face of the patent) | / | |||
| Jan 12 2007 | MACINTYRE, DUNCAN | NIR DIAGNOSTICS INC | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 018811 | /0720 | |
| Jan 12 2007 | KAUSHAL, ASH | NIR DIAGNOSTICS INC | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 018811 | /0720 | |
| Jan 12 2007 | ENDERSBY, PAUL | NIR DIAGNOSTICS INC | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 018811 | /0720 | |
| Jan 22 2009 | NIR DIAGNOSTICS INC | NIRESULTS INC | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 031503 | /0430 | |
| Dec 16 2010 | NIRESULTS INC | Nellcor Puritan Bennett LLC | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 031503 | /0547 | |
| Sep 29 2012 | Nellcor Puritan Bennett LLC | Covidien LP | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 031503 | /0643 |
| Date | Maintenance Fee Events |
| May 23 2017 | M1551: Payment of Maintenance Fee, 4th Year, Large Entity. |
| Jul 26 2021 | REM: Maintenance Fee Reminder Mailed. |
| Jan 10 2022 | EXP: Patent Expired for Failure to Pay Maintenance Fees. |
| Date | Maintenance Schedule |
| Dec 03 2016 | 4 years fee payment window open |
| Jun 03 2017 | 6 months grace period start (w surcharge) |
| Dec 03 2017 | patent expiry (for year 4) |
| Dec 03 2019 | 2 years to revive unintentionally abandoned end. (for year 4) |
| Dec 03 2020 | 8 years fee payment window open |
| Jun 03 2021 | 6 months grace period start (w surcharge) |
| Dec 03 2021 | patent expiry (for year 8) |
| Dec 03 2023 | 2 years to revive unintentionally abandoned end. (for year 8) |
| Dec 03 2024 | 12 years fee payment window open |
| Jun 03 2025 | 6 months grace period start (w surcharge) |
| Dec 03 2025 | patent expiry (for year 12) |
| Dec 03 2027 | 2 years to revive unintentionally abandoned end. (for year 12) |